Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Consensus Recommendation of “Buy” from Brokerages

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has been assigned an average recommendation of “Buy” from the eleven brokerages that are currently covering the company, MarketBeat.com reports. Eleven investment analysts have rated the stock with a buy recommendation. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $64.44.

JSPR has been the subject of a number of research analyst reports. BMO Capital Markets initiated coverage on shares of Jasper Therapeutics in a research note on Friday, December 6th. They issued an “outperform” rating and a $63.00 price target for the company. JMP Securities reaffirmed a “market outperform” rating and issued a $70.00 price objective on shares of Jasper Therapeutics in a report on Monday, January 6th. UBS Group initiated coverage on shares of Jasper Therapeutics in a report on Thursday, February 13th. They issued a “buy” rating and a $38.00 price objective for the company. Royal Bank of Canada decreased their price objective on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a report on Thursday, January 9th. Finally, HC Wainwright decreased their price objective on shares of Jasper Therapeutics from $60.00 to $40.00 and set a “buy” rating for the company in a report on Friday, January 10th.

Jasper Therapeutics Trading Up 4.3 %

Shares of NASDAQ:JSPR opened at $6.25 on Thursday. The company has a fifty day simple moving average of $11.81 and a 200 day simple moving average of $17.28. The firm has a market cap of $93.75 million, a PE ratio of -1.32 and a beta of 2.11. Jasper Therapeutics has a 12-month low of $4.55 and a 12-month high of $31.01.

Hedge Funds Weigh In On Jasper Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets boosted its holdings in shares of Jasper Therapeutics by 208.6% during the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock valued at $47,000 after acquiring an additional 1,698 shares during the period. MetLife Investment Management LLC boosted its holdings in shares of Jasper Therapeutics by 129.1% during the third quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock valued at $129,000 after acquiring an additional 3,873 shares during the period. Wells Fargo & Company MN boosted its holdings in shares of Jasper Therapeutics by 106.7% during the fourth quarter. Wells Fargo & Company MN now owns 7,415 shares of the company’s stock valued at $159,000 after acquiring an additional 3,828 shares during the period. EntryPoint Capital LLC acquired a new stake in Jasper Therapeutics in the fourth quarter worth about $223,000. Finally, Jane Street Group LLC acquired a new stake in Jasper Therapeutics in the third quarter worth about $251,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.